{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:24:33Z","timestamp":1783488273925,"version":"3.55.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T00:00:00Z","timestamp":1455667200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1007\/s40618-016-0441-9","type":"journal-article","created":{"date-parts":[[2016,2,17]],"date-time":"2016-02-17T13:59:15Z","timestamp":1455717555000},"page":"687-694","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Prospective, systematically recorded mycophenolate safety data in Graves\u2019 orbitopathy"],"prefix":"10.1007","volume":"39","author":[{"given":"M.","family":"Riedl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kuhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Kr\u00e4mer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kolbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,2,17]]},"reference":[{"issue":"4","key":"441_CR1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s40618-015-0257-z","volume":"38","author":"L Bartalena","year":"2015","unstructured":"Bartalena L, Macchia PE, Marcocci C, Salvi M, Vermiglio F (2015) Effects of treatment modalities for Graves\u2019 hyperthyroidism on Graves\u2019 orbitopathy: a 2015 Italian Society of Endocrinology Consensus Statement. J Endocrinol Invest 38(4):481\u2013487. doi: 10.1007\/s40618-015-0257-z","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"441_CR2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1007\/s40618-014-0097-2","volume":"37","author":"L Bartalena","year":"2014","unstructured":"Bartalena L, Fatourechi V (2014) Extrathyroidal manifestations of Graves\u2019 disease: a 2014 update. J Endocrinol Invest 37(8):691\u2013700. doi: 10.1007\/s40618-014-0097-2","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"441_CR3","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000356042","volume":"2","author":"L Bartalena","year":"2013","unstructured":"Bartalena L (2013) Graves\u2019 orbitopathy: imperfect treatments for a rare disease. Eur Thyroid J 2(4):259\u2013269. doi: 10.1159\/000356042","journal-title":"Eur Thyroid J"},{"issue":"2","key":"441_CR4","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.mcna.2012.01.014","volume":"96","author":"MN Stan","year":"2012","unstructured":"Stan MN, Garrity JA, Bahn RS (2012) The evaluation and treatment of graves ophthalmopathy. Med Clin North Am 96(2):311\u2013328. doi: 10.1016\/j.mcna.2012.01.014","journal-title":"Med Clin North Am"},{"issue":"9","key":"441_CR5","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","volume":"90","author":"GJ Kahaly","year":"2005","unstructured":"Kahaly GJ, Pitz S, Hommel G, Dittmar M (2005) Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy. J Clin Endocrinol Metab 90(9):5234\u20135240. doi: 10.1210\/jc.2005-0148","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"441_CR6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1007\/BF03346732","volume":"34","author":"S Zang","year":"2011","unstructured":"Zang S, Ponto KA, Pitz S, Kahaly GJ (2011) Dose of intravenous steroids and therapy outcome in Graves\u2019 orbitopathy. J Endocrinol Invest 34(11):876\u2013880","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"441_CR7","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s40618-015-0255-1","volume":"38","author":"F Menconi","year":"2015","unstructured":"Menconi F, Leo M, Vitti P, Marcocci C, Marino M (2015) Total thyroid ablation in Graves\u2019 orbitopathy. J Endocrinol Invest 38(8):809\u2013815. doi: 10.1007\/s40618-015-0255-1","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"441_CR8","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1210\/jc.2014-3014","volume":"100","author":"M Salvi","year":"2015","unstructured":"Salvi M, Vannucchi G, Curro N, Campi I, Covelli D, Dazzi D, Simonetta S, Guastella C, Pignataro L, Avignone S, Beck-Peccoz P (2015) Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves\u2019 orbitopathy: a randomized controlled study. J Clin Endocrinol Metab 100(2):422\u2013431. doi: 10.1210\/jc.2014-3014","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"441_CR9","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1210\/jc.2014-2572","volume":"100","author":"MN Stan","year":"2015","unstructured":"Stan MN, Garrity JA, Carranza Leon BG, Prabin T, Bradley EA, Bahn RS (2015) Randomized controlled trial of rituximab in patients with Graves\u2019 orbitopathy. J Clin Endocrinol Metab 100(2):432\u2013441. doi: 10.1210\/jc.2014-2572","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"441_CR10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2265.2010.03783.x","volume":"73","author":"L Bartalena","year":"2010","unstructured":"Bartalena L (2010) What to do for moderate-to-severe and active Graves\u2019 orbitopathy if glucocorticoids fail? Clin Endocrinol 73(2):149\u2013152. doi: 10.1111\/j.1365-2265.2010.03783.x","journal-title":"Clin Endocrinol"},{"issue":"2\u20133","key":"441_CR11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0162-3109(00)00188-0","volume":"47","author":"AC Allison","year":"2000","unstructured":"Allison AC, Eugui EM (2000) Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 47(2\u20133):85\u2013118","journal-title":"Immunopharmacology"},{"key":"441_CR12","unstructured":"Roche pharmaceuticals AG (2015) German summary of product characteristics. Cellcept"},{"key":"441_CR13","unstructured":"Novartis pharmaceuticals GmbH (2015) German summary of product characteristics. Myfortic"},{"issue":"7","key":"441_CR14","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1016\/S0041-1345(02)03538-8","volume":"34","author":"AC Allison","year":"2002","unstructured":"Allison AC (2002) Mechanisms of action of mycophenolate mofetil in preventing chronic rejection. Transpl Proc 34(7):2863\u20132866","journal-title":"Transpl Proc"},{"issue":"2 Suppl","key":"441_CR15","doi-asserted-by":"crossref","first-page":"S181","DOI":"10.1097\/01.tp.0000186390.10150.66","volume":"80","author":"AC Allison","year":"2005","unstructured":"Allison AC, Eugui EM (2005) Mechanisms of action of mycophenolate mofetil in preventing acute and chronic allograft rejection. Transplantation 80(2 Suppl):S181\u2013S190","journal-title":"Transplantation"},{"key":"441_CR16","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1749-6632.1993.tb35881.x","volume":"685","author":"EM Eugui","year":"1993","unstructured":"Eugui EM, Allison AC (1993) Immunosuppressive activity of mycophenolate mofetil. Ann N Y Acad Sci 685:309\u2013329","journal-title":"Ann N Y Acad Sci"},{"issue":"25","key":"441_CR17","first-page":"423","volume":"112","author":"A Kuhn","year":"2015","unstructured":"Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M (2015) The diagnosis and treatment of systemic lupus erythematosus. Deutsches Arzteblatt international 112(25):423\u2013432. doi: 10.3238\/arztebl.2015.0423","journal-title":"Deutsches Arzteblatt international"},{"issue":"6","key":"441_CR18","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/j.jaad.2010.06.017","volume":"65","author":"A Kuhn","year":"2011","unstructured":"Kuhn A, Ruland V, Bonsmann G (2011) Cutaneous lupus erythematosus: update of therapeutic options part II. J Am Acad Dermatol 65(6):e195\u2013e213. doi: 10.1016\/j.jaad.2010.06.017","journal-title":"J Am Acad Dermatol"},{"key":"441_CR19","author":"YH Lee","year":"2015","unstructured":"Lee YH, Song GG (2015) Relative efficacy and safety of tacrolimus, mycophenolate mofetil, and cyclophosphamide as induction therapy for lupus nephritis: a Bayesian network meta-analysis of randomized controlled trials. Lupus. doi: 10.1177\/0961203315595131","journal-title":"Lupus"},{"key":"441_CR20","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/1471-2369-15-193","volume":"15","author":"Y Chen","year":"2014","unstructured":"Chen Y, Li Y, Yang S, Li Y, Liang M (2014) Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review. BMC Nephrol 15:193. doi: 10.1186\/1471-2369-15-193","journal-title":"BMC Nephrol"},{"issue":"4","key":"441_CR21","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1183\/09031936.00026413","volume":"42","author":"C Grainge","year":"2013","unstructured":"Grainge C, Jayasekera N, Dennison P, Rupani H, Kurukulaaratchy R, Howarth P (2013) Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma. Eur Respir J 42(4):1134\u20131137. doi: 10.1183\/09031936.00026413","journal-title":"Eur Respir J"},{"issue":"3","key":"441_CR22","first-page":"353","volume":"71","author":"W Olejarz","year":"2014","unstructured":"Olejarz W, Bryk D, Zapolska-Downar D (2014) Mycophenolate mofetil\u2014a new atheropreventive drug? Acta Pol Pharm 71(3):353\u2013361","journal-title":"Acta Pol Pharm"},{"issue":"6","key":"441_CR23","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1210\/er.2002-0020","volume":"24","author":"BS Prabhakar","year":"2003","unstructured":"Prabhakar BS, Bahn RS, Smith TJ (2003) Current perspective on the pathogenesis of Graves\u2019 disease and ophthalmopathy. Endocr Rev 24(6):802\u2013835. doi: 10.1210\/er.2002-0020","journal-title":"Endocr Rev"},{"issue":"2","key":"441_CR24","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1097\/WNO.0000000000000132","volume":"34","author":"SJ Shan","year":"2014","unstructured":"Shan SJ, Douglas RS (2014) The pathophysiology of thyroid eye disease. J Neuro Ophthalmol 34(2):177\u2013185. doi: 10.1097\/WNO.0000000000000132","journal-title":"J Neuro Ophthalmol"},{"issue":"3","key":"441_CR25","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","volume":"158","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM, European Group on Graves O (2008) Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO. Eur J Endocrinol Eur Fed Endocr Soc 158(3):273\u2013285. doi: 10.1530\/EJE-07-0666","journal-title":"Eur J Endocrinol Eur Fed Endocr Soc"},{"issue":"3","key":"441_CR26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","volume":"18","author":"L Bartalena","year":"2008","unstructured":"Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Curro N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marino M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM (2008) Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy. Thyroid 18(3):333\u2013346. doi: 10.1089\/thy.2007.0315","journal-title":"Thyroid"},{"issue":"2","key":"441_CR27","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40618-014-0227-x","volume":"38","author":"M Riedl","year":"2015","unstructured":"Riedl M, Kolbe E, Kampmann E, Kramer I, Kahaly GJ (2015) Prospectively recorded and MedDRA-coded safety data of intravenous methylprednisolone therapy in Graves\u2019 orbitopathy. J Endocrinol Invest 38(2):177\u2013182. doi: 10.1007\/s40618-014-0227-x","journal-title":"J Endocrinol Invest"},{"key":"441_CR28","unstructured":"MSSO (2013) MedDRA Term selection: points to consider Release 4.6 Based on MedDRA Version 16.1"},{"key":"441_CR29","unstructured":"ICH (2001) Data elements for transmission of individual case safety reports E2B. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use"},{"key":"441_CR30","unstructured":"ICH (1996) Guideline for good clinical practice E6(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use"},{"issue":"1","key":"441_CR31","first-page":"139","volume":"5","author":"P Dalal","year":"2009","unstructured":"Dalal P, Grafals M, Chhabra D, Gallon L (2009) Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection. Ther Clin Risk Manag 5(1):139\u2013149","journal-title":"Ther Clin Risk Manag"},{"issue":"7","key":"441_CR32","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/j.autrev.2012.10.005","volume":"12","author":"J Sigges","year":"2013","unstructured":"Sigges J, Biazar C, Landmann A, Ruland V, Patsinakidis N, Amler S, Bonsmann G, Kuhn A, Co-Authors E (2013) Therapeutic strategies evaluated by the European Society of Cutaneous Lupus Erythematosus (EUSCLE) Core Set Questionnaire in more than 1000 patients with cutaneous lupus erythematosus. Autoimmun Rev 12(7):694\u2013702. doi: 10.1016\/j.autrev.2012.10.005","journal-title":"Autoimmun Rev"},{"issue":"7","key":"441_CR33","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00007890-199604150-00008","volume":"61","author":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group","year":"1996","unstructured":"The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group (1996) A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61(7):1029\u20131037","journal-title":"Transplantation"},{"issue":"3","key":"441_CR34","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00007890-199508000-00003","volume":"60","author":"HW Sollinger","year":"1995","unstructured":"Sollinger HW (1995) Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 60(3):225\u2013232","journal-title":"Transplantation"},{"issue":"2","key":"441_CR35","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.transproceed.2005.01.063","volume":"37","author":"M Salvadori","year":"2005","unstructured":"Salvadori M, Group ERLS (2005) Long-term administration of enteric-coated mycophenolate sodium in kidney transplant patients. Transpl Proc 37(2):909\u2013911. doi: 10.1016\/j.transproceed.2005.01.063","journal-title":"Transpl Proc"},{"issue":"4","key":"441_CR36","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4174\/astr.2014.86.4.192","volume":"86","author":"JM Kim","year":"2014","unstructured":"Kim JM, Kwon CH, Yun IJ, Lee KW, Yu HC, Suh KS, Joh JW, Cho BH (2014) A multicenter experience with generic mycophenolate mofetil conversion in stable liver transplant recipients. Ann Surg Treat Res 86(4):192\u2013198. doi: 10.4174\/astr.2014.86.4.192","journal-title":"Ann Surg Treat Res"},{"issue":"10","key":"441_CR37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1111\/j.1432-2277.2004.tb00394.x","volume":"17","author":"KL Hardinger","year":"2004","unstructured":"Hardinger KL, Brennan DC, Lowell J, Schnitzler MA (2004) Long-term outcome of gastrointestinal complications in renal transplant patients treated with mycophenolate mofetil. Transpl Int 17(10):609\u2013616. doi: 10.1007\/s00147-004-0768-6","journal-title":"Transpl Int"},{"issue":"6","key":"441_CR38","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/j.1399-0012.2005.00421.x","volume":"19","author":"JC Tierce","year":"2005","unstructured":"Tierce JC, Porterfield-Baxa J, Petrilla AA, Kilburg A, Ferguson RM (2005) Impact of mycophenolate mofetil (MMF)-related gastrointestinal complications and MMF dose alterations on transplant outcomes and healthcare costs in renal transplant recipients. Clin Transpl 19(6):779\u2013784. doi: 10.1111\/j.1399-0012.2005.00421.x","journal-title":"Clin Transpl"},{"issue":"8961","key":"441_CR39","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/S0140-6736(95)92534-1","volume":"345","author":"European Mycophenolate Mofetil Cooperative Study Group","year":"1995","unstructured":"European Mycophenolate Mofetil Cooperative Study Group (1995) Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345(8961):1321\u20131325","journal-title":"Lancet"},{"issue":"6","key":"441_CR40","first-page":"1047","volume":"32","author":"CN Pisoni","year":"2005","unstructured":"Pisoni CN, Sanchez FJ, Karim Y, Cuadrado MJ, D\u2019Cruz DP, Abbs IC, Khamasta MA, Hughes GR (2005) Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients. J Rheumatol 32(6):1047\u20131052","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"441_CR41","doi-asserted-by":"crossref","first-page":"s9","DOI":"10.1177\/096120330501400103","volume":"14","author":"CN Pisoni","year":"2005","unstructured":"Pisoni CN, Karim Y, Cuadrado MJ (2005) Mycophenolate mofetil and systemic lupus erythematosus: an overview. Lupus 14(Suppl 1):s9\u201311","journal-title":"Lupus"},{"issue":"8","key":"441_CR42","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/41.8.876","volume":"41","author":"MY Karim","year":"2002","unstructured":"Karim MY, Alba P, Cuadrado MJ, Abbs IC, D\u2019Cruz DP, Khamashta MA, Hughes GR (2002) Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents. Rheumatology 41(8):876\u2013882","journal-title":"Rheumatology"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0441-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40618-016-0441-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-016-0441-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T12:07:46Z","timestamp":1718366866000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40618-016-0441-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,17]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["441"],"URL":"https:\/\/doi.org\/10.1007\/s40618-016-0441-9","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,17]]}}}